OOIR: Observatory of International Research

Papers

(The median citation count of Drug Metabolism Reviews is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Nano-hydroxyapatite use in dentistry: a systematic review	87
Gold nanostars-diagnosis, bioimaging and biomedical applications	69
Cytochrome P450 expression and regulation in the brain	47
The development and hepatotoxicity of acetaminophen: reviewing over a century of progress	35
Recent biotechnological approaches for treatment of novel COVID-19: from bench to clinical trial	34
Pharmacology of apocynin: a natural acetophenone	30
Drug metabolic stability in early drug discovery to develop potential lead compounds	25
Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions	22
Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects	21
Toxicity mechanisms of nanoparticles in the male reproductive system	20
Pharmacogenomics in the era of next generation sequencing – from byte to bedside	19
Mechanistic studies on the drug metabolism and toxicity originating from cytochromes P450	18
Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease	18
Toxicogenomics of drug induced liver injury – from mechanistic understanding to early prediction.	16
Dioscorea bulbifera L.-induced hepatotoxicity and involvement of metabolic activation of furanoterpenoids	16
Recent developments inin vitroandin vivomodels for improved translation of preclinical pharmacokinetics and pharmacodynamics data	14
The broad-spectrum antiviral recommendations for drug discovery against COVID-19	14
Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts	13
Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases	13
The role of UDP-glycosyltransferases in xenobioticresistance	12
In quest of a new therapeutic approach in COVID-19: the endocannabinoid system	12
Through a glass, darkly? HepaRG and HepG2 cells as models of human phase I drug metabolism	11
What dominates the changeable pharmacokinetics of natural sesquiterpene lactones and diterpene lactones: a review focusing on absorption and metabolism	11
Janus nanoparticles: an efficient intelligent modern nanostructure for eradicating cancer	11
Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review	10

Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs	10
Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia	10
The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy	10
Prediction of drug-induced kidney injury in drug discovery	9
Regulation of human UDP-glycosyltransferase (UGT) genes by miRNAs	9
Towards human ex vivo organ perfusion models to elucidate drug pharmacokinetics in health and disease	9
Bioanalytical strategies in drug discovery and development	9
HLA transgenic mice: application in reproducing idiosyncratic drug toxicity	8
The relationship between UGT1A1 gene & various diseases and prevention strategies	8
Advances in the study of drug metabolism – symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX)	8
Rodent genetic models of Ah receptor signaling	7
Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer dru	7
Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development	6
GSTM1 and GSTT1 polymorphisms in healthy volunteers – a worldwide systematic review	6
Pharmacokinetics, toxicological and clinical aspects of ulipristal acetate: insights into the mechanisms implicated in the hepatic toxicity	6
CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation	6
Novel advances in biotransformation and bioactivation research—2019 year in review	5
Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective	5
Recent developments in predicting CYP-independent metabolism	5
Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice	5
In vitro cell-based models of drug-induced hepatotoxicity screening: progress and limitation	5
Extensive metabolism of flavonoids relevant to their potential efficacy on Alzheimer’s disease	5
Mechanism-based inactivation of cytochrome P450 enzymes by natural products based on metabolic activation	5